StockNews.AI
KMTS
StockNews.AI
165 days

Kestra Medical Technologies, Ltd. Announces Closing of Upsized Initial Public Offering

1. Kestra Medical Technologies closed its IPO raising approximately $202 million. 2. 11,882,352 common shares were offered at $17.00 each. 3. Official trading of KMTS on Nasdaq began on March 6, 2025. 4. Major investment banks led the offering, enhancing market confidence. 5. Kestra focuses on wearable medical devices and digital healthcare innovations.

5m saved
Insight
Article

FAQ

Why Bullish?

The successful IPO with substantial proceeds indicates strong market demand and investor confidence.

How important is it?

The IPO signals financial health and growth potential, which can attract further investment.

Why Short Term?

Short-term boosts are often seen post-IPO if investor sentiment remains high.

Related Companies

BofAGSPiperSandler
March 07, 2025 17:30 ET  | Source: Kestra Medical Technologies, Ltd. KIRKLAND, Wash., March 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, announced today the closing of its upsized initial public offering of 11,882,352 common shares at a public offering price of $17.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kestra, were approximately $202 million. All of the common shares were offered by Kestra. Kestra’s common shares began trading on the Nasdaq Global Select Market on March 6, 2025, under the ticker symbol "KMTS". BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler acted as lead bookrunners for the offering. Wells Fargo Securities and Stifel acted as bookrunners and Wolfe | Nomura Alliance acted as co-manager for the offering. A registration statement relating to the common shares sold in this offering was filed with the Securities and Exchange Commission and became effective on March 5, 2025. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile at 212-902-9316, by email at Prospectus-ny@ny.email.gs.com, or by calling 1-866-471-2526; or Piper Sandler, by email at prospectus@psc.com, or by calling (800) 747-3924. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. Disclaimer “Wolfe | Nomura Alliance” is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura Securities International, Inc. and WR Securities, LLC are serving as underwriters in the offering described herein. In addition, WR Securities, LLC and certain of its affiliates may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with this offering. INVESTOR CONTACTMarissa Bych or Webb CampbellGilmartin Group LLCinvestor.relations@kestramedical.com MEDIA CONTACTRhiannon PickusKestra Medical Technologies, Ltd.Rhiannon.Pickus@kestramedical.com

Related News